Corbus Pharmaceuticals Holdings (CRBP) Profit After Tax (2013 - 2025)

Corbus Pharmaceuticals Holdings' Profit After Tax history runs 13 years deep, the most recent figure standing at -$23.3 million for Q3 2025.

• On a quarterly basis, Profit After Tax fell 69.35% year-over-year to -$23.3 million in Q3 2025; TTM through Sep 2025 was -$67.5 million, a 74.45% decrease from a year earlier, with the FY2024 full-year figure at -$40.2 million, up 9.85% from the prior year.
• Profit After Tax retreated to -$23.3 million in Q3 2025 per CRBP's latest filing, from -$17.7 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$2.2 million in Q3 2021 and bottomed at -$23.3 million in Q3 2025.
• The 5-year median for Profit After Tax is -$10.3 million (2021), against an average of -$12.2 million.
• Across the five-year window, Profit After Tax surged 93.76% in 2021 and sank 307.57% in 2022, its largest moves.
• Year by year, Profit After Tax stood at -$10.3 million in 2021, then slipped by 6.03% to -$10.9 million in 2022, then gained by 26.26% to -$8.0 million in 2023, then slipped by 18.8% to -$9.5 million in 2024, then tumbled by 144.93% to -$23.3 million in 2025.
• Per Business Quant, the three latest CRBP Profit After Tax figures stand at -$23.3 million (Q3 2025), -$17.7 million (Q2 2025), and -$17.0 million (Q1 2025).